首页> 外文期刊>World Journal of Gastroenterology >Preliminary study on proteomics of gastric carcinoma and its clinical significance
【24h】

Preliminary study on proteomics of gastric carcinoma and its clinical significance

机译:胃癌蛋白质组学及其临床意义的初步研究

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To explore the preliminary identification of serum protein pattern models that may be novel potential biomarkers in the detection of gastric cancer. METHODS: A total of 130 serum samples, including 70 from patients with gastric cancer and 60 from healthy adults, were detected by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS). The data of spectra were analyzed by Biomarker Patterns Software (BPS). Thirty serum samples of gastric cancer patients and 30 serum samples of healthy adults were grouped into the training group to build models, and the other 70 samples were used to test and evaluate the models. The samples of the test group were judged only with their peaks' height and were separated into cancer group or healthy control group by BPS automatically and the judgments were checked with the histopathologic diagnosis of the samples. RESULTS: Sixteen mass peaks were found to be potential biomarkers with a significant level of P < 0.01. Among them, nine mass peaks showed increased expression in patients with gastric cancer. Analyzed by BPS, two peaks were chosen to build the model for gastric cancer detection. The sensitivity, specificity, and accuracy of the model were 90%, 36/40, 86.7%, 26/30, and 88.6%, 62/70, respectively, which were greatly higher than those of clinically used serum biomarkers CEA (carcinoembryonic antigen), CA19-9 and CA72-4. Stage Ⅰ/Ⅱ gastric cancer samples of the test group were all judged correctly. CONCLUSION: The novel biomarkers in serum and the established model could be potentially used in the detection of gastric cancer. However, large-scale studies should be carried on to further explore the clinical impact on the model.
机译:目的:探讨血清蛋白模式模型的初步鉴定,这些模型可能是检测胃癌的新型潜在生物标志物。方法:采用表面增强激光解吸和电离飞行时间质谱(SELDI-TOF-MS)检测了130份血清样品,其中包括来自胃癌患者的70份样品和来自健康成年人的60份样品。光谱数据通过Biomarker Patterns软件(BPS)分析。将30例胃癌患者的血清样本和30例健康成人的血清样本分组到训练组中,以建立模型,并使用其他70个样本对模型进行测试和评估。仅通过峰高判断测试组样品,并通过BPS自动将其分为癌症组或健康对照组,并通过样品的组织病理学诊断检查该判断。结果:发现十六个质量峰是潜在的生物标志物,其显着水平为P <0.01。其中,有9个质谱峰表明胃癌患者的表达增加。通过BPS分析,选择了两个峰以建立胃癌检测模型。该模型的敏感性,特异性和准确性分别为90%,36 / 40、86.7%,26/30和88.6%,62/70,远高于临床使用的血清生物标志物CEA(癌胚抗原) ),CA19-9和CA72-4。对试验组Ⅰ/Ⅱ期胃癌标本均正确判断。结论:血清中的新型生物标志物和建立的模型可用于胃癌的检测。但是,应该进行大规模研究以进一步探索对该模型的临床影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号